Abstract Number: 2074 • 2017 ACR/ARHP Annual Meeting
A Series of Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Studies to Evaluate the Efficacy, Safety, and Dose-Response Relationship of Orally Administered URC102, a Novel URAT1 Inhibitor, in Korean Patients with Gout
Background/Purpose: URC102 is a novel URAT1 inhibitor under clinical development for the treatment of hyperuricemia with gout. A series of double-blind, placebo-controlled, randomized, multicenter, phase…Abstract Number: 2075 • 2017 ACR/ARHP Annual Meeting
The Effect of Uric Acid Lowering Treatment on the Microbiome in Gout Patients
Background/Purpose: Accumulating evidence indicates that gut microbiota interact with gout but it is still unknown how the uric acid lowering treatment (ULT) affects to the…Abstract Number: 2077 • 2017 ACR/ARHP Annual Meeting
Statin Use and Mortality in Gout: A General Population-Based Cohort Study
Background/Purpose: Although the cardinal feature of gout is inflammatory arthritis, it is also a metabolic condition closely associated with an elevated uric acid burden and…Abstract Number: 2082 • 2017 ACR/ARHP Annual Meeting
Clinical Presentation, Management, and Prognosis of Pseudogout in Prosthetic Joint Implant Patients: A Retrospective Study
Background/Purpose: The prevalence of total knee arthroplasty (TKA) and total hip arthroplasty (THA) has risen considerably in the U.S. There has been a relative lack…Abstract Number: 2084 • 2017 ACR/ARHP Annual Meeting
Patients with Early Onset Gout Develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions
Patients with Early Onset Gout develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions Background/Purpose: Early onset gout might encompass more severe cases along with genetic defects,…Abstract Number: 2085 • 2017 ACR/ARHP Annual Meeting
Relationship between Gout and Asthma: A National Database Analysis
Background/Purpose: Gout is an inflammatory disorder related to hyperuricemia and abnormal deposition of monosodium urate crystals in joints or other tissues. The relationship between serum…Abstract Number: 2087 • 2017 ACR/ARHP Annual Meeting
Allelic Variants of ABCG2 and Gout Risk
Background/Purpose: Common dysfunctional variants of ABCG2, a high-capacity urate transporter gene, that result in decreased urate excretion, are major causes of hyperuricemia and gout. In…Abstract Number: 2091 • 2017 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies
Background/Purpose: Pegylated uricases are promising therapies for the treatment of severe chronic gout, particularly for the rapid resolution of tophi. However uricases are limited…Abstract Number: 2250 • 2017 ACR/ARHP Annual Meeting
Linguistic Differences in Gout-Related Online Content: A Comparison of Professional Health Literature for Consumers Vs Patients’ Online Discussions of Gout
Background/Purpose: Non-adherence to gout medication is high. This may be due in part to patients’ belief that gout is primarily caused by overindulgence in certain…Abstract Number: 2265 • 2017 ACR/ARHP Annual Meeting
Survey on Gout-Related Knowledge and Perception in Inpatient Setting on Hospitalized Patients with Gout
Background/Purpose: The increasing global burden of gout disease and its impact on the patient’s quality of life calls for new strategies in management. Even though…Abstract Number: 2843 • 2017 ACR/ARHP Annual Meeting
The Relationship between Serum Urate Concentration and Incident Gout: An Individual Participant Data Analysis
Background/Purpose: Elevated serum urate concentration (hyperuricemia) is considered to be a key risk factor for developing gout. However, the relationship between serum urate and incident…Abstract Number: 2844 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Febuxostat Versus Allopurinol: A Population-Based Cohort Study
Background/Purpose: Gout, a disorder of uric acid deposition, is commonly treated with xanthine oxidase inhibitors like febuxostat and allopurinol. While it is well-known that patients…Abstract Number: 2845 • 2017 ACR/ARHP Annual Meeting
Association between Serum Urate As a Surrogate Endpoint and Flares in People with Gout: An Ecological Study Based on a Systematic Review of Trials and Open Label Extensions
Background/Purpose: The primary efficacy measure in urate lowering therapy (ULT) trials is usually serum urate (SU). However, it is unknown whether the strength of the…Abstract Number: 2846 • 2017 ACR/ARHP Annual Meeting
Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Renal-Related and Decreased Risk of Dementia-Related Death
Background/Purpose: There is recognized higher mortality among gout patients, with cardiovascular (CV) mortality having been previously reported. The present study aimed to examine cause-specific mortality…Abstract Number: 2847 • 2017 ACR/ARHP Annual Meeting
The Sons of Gout Study. Ultrasonographic Evaluation of Asymptomatic Monosodium Urate Crystal Deposition in Sons of People with Gout
Background/Purpose: Hyperuricemia and gout aggregate in families. The objectives of this study were to estimate the prevalence of asymptomatic monosodium urate (MSU) crystal deposition in…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »